INVESTOR PRESENTATION DESERT HOPE ALUMNI NOVEMBER 2016 IMPORTANT - - PowerPoint PPT Presentation

investor presentation
SMART_READER_LITE
LIVE PREVIEW

INVESTOR PRESENTATION DESERT HOPE ALUMNI NOVEMBER 2016 IMPORTANT - - PowerPoint PPT Presentation

INVESTOR PRESENTATION DESERT HOPE ALUMNI NOVEMBER 2016 IMPORTANT PRESENTATION INFORMATION 2 We use market data and industry forecasts and projections throughout this presentation, including data from publicly available information and industry


slide-1
SLIDE 1

INVESTOR PRESENTATION

NOVEMBER 2016

DESERT HOPE ALUMNI

slide-2
SLIDE 2

IMPORTANT PRESENTATION INFORMATION

2

Notice to Investors

We use market data and industry forecasts and projections throughout this presentation, including data from publicly available information and industry publications. These sources generally state that the information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of the information are not guaranteed. The forecasts and projections are based on industry surveys and the preparers’ experience in the industry, and there can be no assurance that any of the forecasts or projections will be achieved. We believe that the surveys and market research others have performed are reliable, but we have not independently investigated or verified this information. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements contained in this presentation.

Forward-Looking Statements

Some of the statements made in this presentation constitute forward-looking statements within the meaning of federal securities laws. Forward-looking statements reflect our current views with respect to future events and performance. In some cases you can identify forward-looking statements by terminology such as “may,” “might, “will,” “should,” “could” or the negative thereof. Generally, the words “anticipate,” “believe,” “continues,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our pipeline, industry growth opportunities, disclosure of key performance indicators, business growth strategy and financial guidance in this presentation are forward-looking statements. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties and

  • ther factors, many of which are outside of our control, which could cause our actual results, performance or achievements to differ materially from any results,

performance or achievements expressed or implied by such forward-looking statements. For additional discussion of risks, uncertainties and other factors, see the section titled “Risk Factors” in our Annual Report on Form 10-K and other filings with the Securities and Exchange Commission (the "SEC"). Risks, uncertainties and other factors include, without limitation: (i) our inability to operate our facilities; (ii) our reliance on our sales and marketing program to continuously attract and enroll clients; (iii) a reduction in reimbursement rates by certain third-party payors for inpatient and outpatient services and point of care and definitive lab testing; (iv) our failure to successfully achieve growth through acquisitions and de novo expansions; (v) uncertainties regarding the timing of the closing of acquisitions; (vi) our failure to achieve anticipated financial results from prior acquisitions; (vii) the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the acquisitions; (viii) a disruption in our ability to perform definitive drug testing services; (ix) maintaining compliance with applicable regulatory authorities, licensure and permits to operate our facilities and lab; (x) a disruption in our business and reputation and potential economic consequences with the civil securities claims brought by shareholders; (xi) our inability to agree on conversion and other terms for the balance of convertible debt; (xii)

  • ur inability to meet our covenants in our loan documents; (xiii) our inability to obtain senior lender consent to exceed the current $50 million limit in unsecured

subordinated debt; (xiv) our inability to integrate newly acquired facilities; and (xv) general economic conditions, as well as other risks discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and other filings with the SEC. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date

  • f this presentation. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to

any such statements to reflect future events or developments.

slide-3
SLIDE 3

PRESENTERS

  • Founder and CEO of Foundations Recovery Network
  • At Foundations, opened notable treatment facilities including the Canyon in

Malibu, La Paloma in Memphis and Michael’s House in Palm Springs

  • Started Moments of Change & Lifestyle Intervention, two of the leading

national industry conferences

  • Author of Believable Hope
  • Almost 20 years of management experience
  • Founder and Managing Member of Private Capital Securities, a boutique

investment banking firm

  • Former Vice President at Piper Jaffray and Fixed Income Specialist with

Stephens Inc.

  • Co-founder and CEO of four communications companies including Igaea, an

international VoIP Company

  • 23+ years management experience

Michael T. Cartwright

Chairman

(since 2011)


Chief Executive Officer

(since 2013) michael@contactaac.com


 Kirk R. Manz

Chief Financial Officer

(since 2011) kmanz@contactaac.com

3

slide-4
SLIDE 4

AAC: AT A GLANCE

4

> AAC Holdings, Inc. (“AAC”), the parent of American Addiction Centers, Inc.

  • Headquartered in Brentwood, Tennessee
  • Operates 12 residential alcohol and drug addiction treatment facilities in California, Florida, Louisiana,

Mississippi, Nevada, New Jersey and Texas

  • Operates 18 standalone outpatient centers in Nevada, Louisiana, Mississippi, New Jersey, Rhode Island and

Texas

  • TTM revenue of $266 million revenue up 25% from $212 million revenue in 2015
  • Approx. 94% of reimbursements from commercial payors
  • Over 1,300 detoxification, residential and sober living beds currently with over 300 beds in pipeline
  • Approximately 2,200 employees
  • Engaged board of directors with strong healthcare & public company experience
  • Invested executive management and board - own majority of outstanding stock

AAC IS A LEADING PROVIDER OF INPATIENT DRUG AND ALCOHOL ADDICTION TREATMENT SERVICES 
 IN THE BEHAVIORAL HEALTH SECTOR

slide-5
SLIDE 5

FACILITIES FOOTPRINT

5

Laguna Treatment Hospital Desert Hope Forterus SDTC Greenhouse Headquarters Oxford River Oaks Recovery First Recovery First West Palm Sunrise House Ringwood* * Pending Solutions Recovery Townsend Sagenex Labs Addiction Labs Out-of-Network Residential Facility In-Network Residential Facility In-Network Outpatient Facility Out-of-Network Outpatient Facility Out-of-Network Laboratory In-Network Laboratory CSRI Sober Living Beds In/Out-of-Network Residential Facility In/Out-of-Network Outpatient Facility

slide-6
SLIDE 6

AAC: CHANGING EVOLUTION OF OUR BUSINESS

6

> Payor mix is diversifying

  • At IPO, AAC reimbursements were almost entirely


Out-of-Network commercial reimbursements

  • In two years, AAC has diversified its payor mix to 


72% Out-of-Network, 22% In-Network

  • AAC anticipates continuing to diversify payor mix to include more

in-network commercial insurance, private pay and possible government pay options

> Service lines are expanding

  • At IPO, AAC revenue was almost entirely residential
  • In two years, AAC has diversified its service lines to include stand

alone lab, lower acuity outpatient centers and a higher acuity hospital

  • AAC anticipates continuing to expand lower acuity outpatient

centers, higher acuity hospital locations while diversifying its lab to include 3rd party

AAC HAS MATERIALLY DIVERSIFIED ITS PAYOR MIX AND SERVICE LINES SINCE GOING PUBLIC

Individual 6% Out-of-Network 72% In-Network 22% Individual 8% Out-of-Network 92% Residential 94% Laboratory 6% Hospital 2% Residential 74% Outpatient 8% Laboratory 16%

IPO SEPT 30, 2016

PAYORS SERVICES

IPO SEPT 30, 2016

slide-7
SLIDE 7

DEBT OVERVIEW

7

2015 - Q4 2016 - Q1 2016 - Q2 2016 - Q3 2016 - Q3 2016 - Q4 Senior Credit Facility $95,141 $93,088 $117,523 $139,426 $129,426 $139,426 Deerfield Convertible Debt $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 Deerfield Subordinated Debt $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 Total Debt $145,141 $143,088 $167,523 $189,426 $179,426 $189,426 Cash On Hand $18,750 $13,237 $7,269 $13,276 $13,276 $10,000 Net Debt $126,391 $129,851 $160,254 $176,150 $166,150 $176,150 Trailing 12 Months AEBITDA $44,277 $47,510 $45,610 $46,006 $46,006 $47,000 Senior Leverage (Net Debt) 2.15 1.68 2.42 2.74 2.52 2.75 Total Leverage (Net Debt) 2.85 2.73 3.51 3.83 3.61 3.82 Collateral Property and equipment, net $109,724 $111,972 $128,623 $136,171 $136,171 $136,171 Accounts receivable, net of allowances $60,934 $62,922 $74,692 $80,410 $80,410 $80,410 Cash $18,750 $13,237 $7,269 $13,276 $13,276 $10,000 Total Collateral $189,408 $188,131 $210,584 $229,857 $229,857 $226,581 Collateral Coverage 1.3 1.3 1.3 1.2 1.3 1.2

> Current construction projects (approximately $25MM) expected to be funded with cash on hand & free cash flow > Senior Leverage Net Debt currently at 2.74X; projected to remain stable through year end and in 2017 > Strong collateral provides 1.2X coverage on Total Debt

ABSENT CA MATTER PROJECTED

dollars in thousands

slide-8
SLIDE 8

1,000 2,000 3,000 4,000

Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6

3,258 2,890 2,623 2,462 1,980 1,806 1,515

OPERATING METRICS

8

250 500 750 1,000

Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6

853 821 764 670 560 539 480

0MM 20MM 40MM 60MM

Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6

$48.2 $43.9 $43.6 $41.6 $37.8 $31.5 $27.6

REVENUE

  • AVG. DAILY CENSUS

ADMISSIONS

5,000 10,000 15,000 20,000

Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6

15,299 13,079 4,978 4,328 4,329 2,634 1,588

VISITS

0MM 1MM 2MM 3MM 4MM 5MM

Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6

$5.0 $4.0 $1.9 $1.7 $2.1 $2.1 $0.8

REVENUE

100 200 300 400 500

Q 1 ' 1 5 Q 2 ' 1 5 Q 3 ' 1 5 Q 4 ' 1 5 Q 1 ' 1 6 Q 2 ' 1 6 Q 3 ' 1 6

432 381 153 160 127 60 14

  • AVG. DAILY CENSUS

RESIDENTIAL OUTPATIENT

slide-9
SLIDE 9

3RD PARTY LAB SALES

9

> Key selling propositions

  • Faster turn around
  • One stop for:
  • Toxicology
  • General Clinical Testing
  • hematology, chemistry, infectious disease, hormone, urinalysis)
  • Pharmacogenetics
  • Addiction only focus
  • Superior test reporting and EMR integration

> 3rd party sales just now coming online; primary focus of management team

  • 3 sales representatives + 1 sales manager currently
  • Anticipate adding 2-3 more additional reps within 2-3 months
  • YTD revenue of $700K
  • Active clients represent $2 - $3MM of projected annualized revenue
  • Current sales pipeline represents $3 - $7MM of projected annual revenue

20 ACCOUNTS AVERAGING AN ADC OF 50 CLIENTS COULD DOUBLE CURRENT TESTING VOLUMES

  • 2 lab locations: Nashville, New Orleans
  • 16 liquid chromatography mass spectrometry machines (LC-MS) - toxicology


3 enzymatic immunoassay machines (EIA) - toxicology, general clinical testing 
 1 polymerase chain reaction machine (PCR) - DNA

  • Currently at 30% utilization (AAC clients)
slide-10
SLIDE 10

> Benefits:

  • Frees approximately 30% bed capacity at

Desert Hope / Greenhouse

  • Lower investment cost per bed 


($80K per sober living bed versus $125K residential bed)

  • Facilitates outpatient visits
  • Opportunity to increase length of stay per

residential admit

  • 100 beds can facilitate up to $5 million of

annual outpatient revenue

> Resolutions Las Vegas

  • 86 active beds
  • 14 beds under construction

> Resolutions Arlington

  • 30 active beds
  • 70 beds under construction

SOBER LIVING

10

slide-11
SLIDE 11

> Legacy facility DSO’s have remained stable > Payor requests for clinical documentation (physician orders and test results) have extended lab collection days > Declining lab revenue in Q3 ’16 contributed to increase in lab DSO’s quarter over quarter

DSO'S

11

DSO Roll Up 2015 - Q4 2016 - Q1 2016 - Q2 2016 - Q3 Legacy1 78 76 79 77 Acquisitions / De Novo2 1 4 2 5 Professional Group’s / Other

  • 3
  • 6
  • 1

Lab 20 14 14 24 Total 96 88 95 105

1Greenhouse; Desert Hope; Forterus, San Diego; Singer Island; Greenhouse Outpatient Center; Desert Hope Outpatient Center, Recovery First; CSRI; Sunrise 2River Oaks; Laguna; Oxford; Townsend; Sagenex; Solutions Recovery

DSO’S AT LEGACY FACILITIES HAVE BEEN STABLE RECENT INCREASES IN DSO’S HAVE BEEN DRIVEN BY ACQUISITIONS, DE NOVO’S AND LAB

Days Sales Outstanding = quarter end Accounts Receivable balance, Net of Provision divided by Average Daily Sales (Net Revenue for the quarter divided by number of days in period)

slide-12
SLIDE 12

CORPORATE OVERHEAD ANALYSIS

12

Q1-FY15 Q2-FY15 Q3-FY15 Q4-FY15 Q1-FY16 Q2-FY16 Q3-FY16 Client Revenue $42,822,645 $53,784,428 $53,694,831 $55,450,126 $62,408,786 $68,161,910 $68,491,512 ADC 480 539 560 670 764 821 853 Admits 1,588 1,806 1,980 2,462 2,623 2,890 3,258 Employees 986 1,126 1,501 1,766 1,756 2,185 2,107 Corp Overhead $6,877,238 $7,126,099 $8,264,184 $8,876,363 $11,082,490 $11,431,715 $9,690,994 % of Client Revenue 16.1% 13.2% 15.4% 16.0% 17.8% 16.8% 14.1% Cost Per ADC $14,328 $13,221 $14,757 $13,248 $14,506 $13,924 $11,361 Cost Per Admit $4,331 $3,947 $4,174 $3,605 $4,225 $3,956 $2,975 Cost Per Employee $6,975 $6,329 $5,506 $5,026 $6,311 $5,233 $4,599 CRMS Billing Expenses $890,887 $1,036,878 $1,221,359 $1,132,630 $1,745,098 $1,506,602 $1,599,724 % of Client Revenue 2.1% 1.9% 2.3% 2.0% 2.8% 2.2% 2.3% Sales & Marketing, Net of RB Revenue1 $8,560,808 $9,367,644 $8,844,859 $8,926,730 $9,282,308 $11,355,454 $11,636,555 Cost Per Admit $5,391 $5,188 $4,467 $3,626 $3,539 $3,929 $3,572

> Corporate overhead has remained relatively flat as a % of client revenue - opportunity to improve margins by reducing expenses > Billing expenses have remained relatively flat at less than 2.5% - expected to remain flat as % of revenue going forward > Customer acquisition costs have dramatically decreased - potential for additional improvement with more placement options

1Includes SW&B for business development, call center, Recovery Brands, Taj Media, and corporate marketing departments LESS revenue generated from Recovery Brands

slide-13
SLIDE 13

KEY INVESTMENT HIGHLIGHTS

13

> American Addiction Centers, Inc. (“AAC”)

  • Large and growing market - Mental Health and Substance Abuse Centers and Clinics represent $31B market (1)
  • Important public need - drug overdose is the leading cause of accidental death (2)
  • Favorable legislative tailwinds - Mental Health Parity & Addiction Equity Act and Affordable Care Act
  • Highly fragmented industry ripe for consolidation - 28,600 treatment clinics and centers operated by over 19,200 enterprises (1) 


(4 largest players < 10% market share (1))

  • Passionate about clinical excellence - AAC is committed to outcome studies and continual quality improvement
  • Consumer driven service a perfect fit for a national brand - AAC averaging 2 million+ sites visits & 35,000 inbound calls per month
  • Leading high growth platform in behavioral niche - AAC 50% 5 YR CAGR
  • Strong organic track record and de novo pipeline - AAC has 1,300 beds currently and 300 beds in pipeline
  • Diversified payor base - no single payor represents more than 11% of AAC’s revenue reimbursements (3)
  • Experienced management team with established track record in the industry
  • Significant operating leverage - AAC able to scale bed capacity with relatively low fixed overhead

AAC IS A LEADING PROVIDER OF INPATIENT AND OUTPATIENT DRUG AND ALCOHOL ADDICTION TREATMENT SERVICES

(1) 2015 IBISWorld (2) Centers for Disease Control and Prevention (3) For nine months ended September 30, 2016

slide-14
SLIDE 14

APPENDIX: NON-GAAP FINANCIAL MEASURES

14

Adjusted EBITDA, adjusted net income available to AAC Holdings, Inc. stockholders, and adjusted diluted earnings per share (herein collecYvely referred to as “Non-GAAP Disclosures”) are “non-GAAP financial measures” as defined under the rules and regulaYons promulgated by the SEC. Management defines Adjusted EBITDA as net income adjusted for interest expense, depreciaYon and amorYzaYon expense, income tax expense, stock-based compensaYon and related tax reimbursements, liYgaYon se_lement and California ma_er related expense, acquisiYon-related expense (which includes professional services for accounYng, legal, valuaYon services and licensing expenses), de novo start-up expenses, facility closure operaYng losses and expense associated with The Academy and FitRx in the fourth quarter of 2015, and bargain purchase gain associated with our acquisiYon of Sunrise House in the fourth quarter of 2015. Management defines Adjusted Net Income Available to AAC Holdings, Inc. stockholders as net income available to AAC Holdings, Inc. stockholders adjusted for liYgaYon se_lement and California ma_er related expense, acquisiYon-related expense (which includes professional services for accounYng, legal, valuaYon services and licensing expenses), de novo start-up expenses, facility closure operaYng losses and expense associated with The Academy and FitRx, bargain purchase gain associated with our acquisiYon of Sunrise House in the fourth quarter

  • f 2015, redempYon of BHR Series A Preferred Units, and the income tax effect of the non-GAAP adjustments at the then applicable effecYve tax rate.

The Non-GAAP Disclosures are considered supplemental measures of the Company’s performance and are not required by, or presented in accordance with, generally accepted accounYng principles, or GAAP. The Non-GAAP Disclosures are not measures of the Company’s financial performance under GAAP and should not be considered as an alternaYve to net income or any

  • ther performance measures derived in accordance with GAAP. Management has included informaYon concerning Non-GAAP Disclosures because they believe that such informaYon is used

by certain investors as a measure of a company’s historical performance. Management believes these measures are frequently used by securiYes analysts, investors and other interested parYes in the evaluaYon of issuers of equity securiYes, many of which present EBITDA, Adjusted EBITDA and Adjusted EPS when reporYng their results. Because Non-GAAP Disclosures are not determined in accordance with GAAP, they are subject to varying calculaYons and may not be comparable to similarly Ytled measures of other companies. Management’s presentaYon of Non-GAAP Disclosures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

slide-15
SLIDE 15

RECONCILIATION OF NON-GAAP DISCLOSURES

15

September 30, 2016 June 30, 2016 March 31, 2016 December 31, 2015

Net (loss) income $ (5,076) $ 679 $ 5,953 $ 8,341 Non-GAAP Adjustments: Interest expense 7,031 6,307 4,568 3,607 Depreciation and amortization 15,669 12,961 10,412 7,837 Income tax (benefit) expense (1,108) 294 3,415 4,780 Stock-based compensation and related tax reimbursements 8,452 7,658 6,762 5,757 Litigation settlement and California matter related expense 9,275 7,562 # 7,751 # 5,446 Acquisition-related expense 3,606 3,979 # 3,663 # 3,801 De novo start-up expense and other 8,045 5,474 4,231 3,369 Facility closure operating losses and expense 1,887 2,471 2,530 3,114 Bargain purchase gain (1,775) (1,775) (1,775) (1,775) Adjusted EBITDA $ 46,006 $ 45,610 $ 47,510 $ 44,277

Trailing Twelve Months Ended

AAC HOLDINGS, INC. SUPPLEMENTAL RECONCILIATION OF NON-GAAP DISCLOSURES Unaudited Reconciliation of Trailing Twelve Months (TTM) Adjusted EBITDA to Net Income (Loss)